Literature DB >> 14638778

Intestinal antilectin immunoglobulin A antibody response and immunity to Entamoeba dispar infection following cure of amebic liver abscess.

Jonathan I Ravdin1, Mohamed D Abd-Alla, Seth L Welles, Selvan Reddy, Terry F H G Jackson.   

Abstract

We followed 93 subjects with amebic liver abscess (ALA) and 963 close associate controls at 3-month intervals for 36 months to characterize intestinal and humoral antibody responses to the amebic galactose-inhibitable lectin and to determine whether immunity developed to Entamoeba histolytica or Entamoeba dispar infection following cure of ALA. We found that ALA subjects had a higher prevalence and level of intestinal antilectin immunoglobulin A (IgA) and serum anti-LC3 (cysteine-rich recombinant lectin protein) IgA and IgG antibodies, P < 0.01 and P < 0.05, respectively, compared to controls. The intestinal antilectin IgA antibody response was sustained over a longer time period in ALA subjects (71.8% remained positive at 18 months and 52.6% at 36 months, P < 0.001 compared to 17.6% and 10.3% of controls, respectively). ALA subjects were highly immune to E. dispar infection throughout the study (0% infected at 6 and 36 months, compared to 6.5% and 4.9% of control subjects, respectively, P < 0.05). Upon entry into the study, 6.3% of ALA subjects were infected with E. histolytica; the incidence of new E. histolytica infections in controls (as determined by culture) was too low (1.4%) to determine whether ALA subjects exhibited immunity to new infections. We found that stool cultures every 3 months markedly underestimated the occurrence of new E. histolytica infections, as 15.3% of controls seroconverted after 12 months of follow-up. Unfortunately, under the field conditions present in Durban, South Africa, enzyme-linked immunosorbent assay for detection of lectin antigen in stool yielded unreliable results. In summary, subjects cured of ALA exhibited sustained mucosal IgA antibody responses to the amebic galactose-inhibitable lectin and a high level of immunity to E. dispar infection. Determination of immunity to E. histolytica following cure of ALA will require the use of more sensitive and reliable diagnostic methods.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14638778      PMCID: PMC308927          DOI: 10.1128/IAI.71.12.6899-6905.2003

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  31 in total

1.  A comparison of cross-sectional and longitudinal seroepidemiological assessments of entamoeba-infected populations in South Africa.

Authors:  T Jackson; S Reddy; J Fincham; M Abd-Alla; S Welles; J Ravdin
Journal:  Arch Med Res       Date:  2000 Jul-Aug       Impact factor: 2.235

2.  Entamoeba dispar: molecular characterization of the galactose/N-acetyl-d-galactosamine lectin.

Authors:  D R Pillai; S Kobayashi; K C Kain
Journal:  Exp Parasitol       Date:  2001-12       Impact factor: 2.011

3.  Amebiasis and mucosal IgA antibody against the Entamoeba histolytica adherence lectin in Bangladeshi children.

Authors:  R Haque; I M Ali; R B Sack; B M Farr; G Ramakrishnan; W A Petri
Journal:  J Infect Dis       Date:  2001-05-15       Impact factor: 5.226

4.  Diagnosis of amebic liver abscess and intestinal infection with the TechLab Entamoeba histolytica II antigen detection and antibody tests.

Authors:  R Haque; N U Mollah; I K Ali; K Alam; A Eubanks; D Lyerly; W A Petri
Journal:  J Clin Microbiol       Date:  2000-09       Impact factor: 5.948

5.  Real-time PCR for detection and differentiation of Entamoeba histolytica and Entamoeba dispar in fecal samples.

Authors:  Joerg Blessmann; Heidrun Buss; Phuong A Ton Nu; Binh T Dinh; Quynh T Viet Ngo; An Le Van; Mohamed D Abd Alla; Terry F H G Jackson; Jonathan I Ravdin; Egbert Tannich
Journal:  J Clin Microbiol       Date:  2002-12       Impact factor: 5.948

6.  Comparison of antigen-capture ELISA to stool-culture methods for the detection of asymptomatic Entamoeba species infection in Kafer Daoud, Egypt.

Authors:  M D Abd-Alla; A A Wahib; J I Ravdin
Journal:  Am J Trop Med Hyg       Date:  2000-05       Impact factor: 2.345

7.  Epidemiology of amebiasis in a region of high incidence of amebic liver abscess in central Vietnam.

Authors:  Joerg Blessmann; Pham Van Linh; Phuong Anh Ton Nu; Hao Duong Thi; Bertram Muller-Myhsok; Heidrun Buss; Egbert Tannich
Journal:  Am J Trop Med Hyg       Date:  2002-05       Impact factor: 2.345

8.  Use of an enzyme-linked immunosorbent assay to detect anti-adherence protein antibodies in sera of patients with invasive amebiasis in Cairo, Egypt.

Authors:  M D Abd-Alla; A M el-Hawey; J I Ravdin
Journal:  Am J Trop Med Hyg       Date:  1992-12       Impact factor: 2.345

9.  Genotyping of Entamoeba species in South Africa: diversity, stability, and transmission patterns within families.

Authors:  Mehreen Zaki; Selvan G Reddy; Terry F H G Jackson; Jonathan I Ravdin; C Graham Clark
Journal:  J Infect Dis       Date:  2003-06-04       Impact factor: 5.226

10.  Innate and acquired resistance to amebiasis in bangladeshi children.

Authors:  Rashidul Haque; Priya Duggal; Ibnekarim M Ali; Mohammad Bakthiar Hossain; Dinesh Mondal; R Bradley Sack; Barry M Farr; Terri H Beaty; William A Petri
Journal:  J Infect Dis       Date:  2002-07-19       Impact factor: 5.226

View more
  9 in total

1.  Mucosal immunity to asymptomatic Entamoeba histolytica and Entamoeba dispar infection is associated with a peak intestinal anti-lectin immunoglobulin A antibody response.

Authors:  Mohamed D Abd-Alla; Terry F G H Jackson; Tyson Rogers; Selvan Reddy; Jonathan I Ravdin
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

2.  Protection against intestinal amebiasis by a recombinant vaccine is transferable by T cells and mediated by gamma interferon.

Authors:  Xiaoti Guo; Lisa Barroso; Steven M Becker; David M Lyerly; Thomas S Vedvick; Steven G Reed; William A Petri; Eric R Houpt
Journal:  Infect Immun       Date:  2009-06-29       Impact factor: 3.441

Review 3.  The future for vaccine development against Entamoeba histolytica.

Authors:  Jeanie Quach; Joëlle St-Pierre; Kris Chadee
Journal:  Hum Vaccin Immunother       Date:  2014-02-06       Impact factor: 3.452

4.  Entamoeba histolytica infection in children and protection from subsequent amebiasis.

Authors:  Rashidul Haque; Dinesh Mondal; Priya Duggal; Mamun Kabir; Shantanu Roy; Barry M Farr; R Bradley Sack; William A Petri
Journal:  Infect Immun       Date:  2006-02       Impact factor: 3.441

5.  Comparative genomic hybridizations of Entamoeba strains reveal unique genetic fingerprints that correlate with virulence.

Authors:  Preetam H Shah; Ryan C MacFarlane; Dhruva Bhattacharya; John C Matese; Janos Demeter; Suzanne E Stroup; Upinder Singh
Journal:  Eukaryot Cell       Date:  2005-03

6.  Adherence-inhibitory intestinal immunoglobulin a antibody response in baboons elicited by use of a synthetic intranasal lectin-based amebiasis subunit vaccine.

Authors:  Mohamed D Abd Alla; Gary L White; Tyson B Rogers; Max E Cary; David W Carey; Jonathan I Ravdin
Journal:  Infect Immun       Date:  2007-05-25       Impact factor: 3.441

7.  Identification of the Entamoeba histolytica galactose-inhibitable lectin epitopes recognized by human immunoglobulin A antibodies following cure of amebic liver abscess.

Authors:  Mohamed D Abd-Alla; Terry F G H Jackson; Ginny C Soong; Mary Mazanec; Jonathan I Ravdin
Journal:  Infect Immun       Date:  2004-07       Impact factor: 3.441

Review 8.  Immune Response of Amebiasis and Immune Evasion by Entamoeba histolytica.

Authors:  Kumiko Nakada-Tsukui; Tomoyoshi Nozaki
Journal:  Front Immunol       Date:  2016-05-12       Impact factor: 7.561

Review 9.  Entamoeba histolytica: adhesins and lectins in the trophozoite surface.

Authors:  Magdalena Aguirre García; Laila Gutiérrez-Kobeh; Rosario López Vancell
Journal:  Molecules       Date:  2015-02-09       Impact factor: 4.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.